Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Operating Leases (2019 - 2026)

ADC Therapeutics has reported Operating Leases over the past 8 years, most recently at $991000.0 for Q1 2026.

  • Quarterly results put Operating Leases at $991000.0 for Q1 2026, down 87.47% from a year ago — trailing twelve months through Mar 2026 was $991000.0 (down 87.47% YoY), and the annual figure for FY2025 was $1.0 million, down 87.07%.
  • Operating Leases reached $991000.0 in Q1 2026 per ADCT's latest filing, down from $1.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $11.0 million in Q1 2023 and bottomed at $991000.0 in Q1 2026.
  • Median Operating Leases over the past 5 years was $7.9 million (2025), compared with a mean of $6.9 million.
  • The largest annual shift saw Operating Leases skyrocketed 93751.87% in 2022 before it crashed 87.47% in 2026.
  • Over 5 years, Operating Leases stood at $6.6 million in 2022, then soared by 55.09% to $10.2 million in 2023, then fell by 21.46% to $8.0 million in 2024, then tumbled by 87.07% to $1.0 million in 2025, then dropped by 4.16% to $991000.0 in 2026.
  • Business Quant data shows Operating Leases for ADCT at $991000.0 in Q1 2026, $1.0 million in Q4 2025, and $2.1 million in Q3 2025.